The research presented in "Structural basis of human GHRHR conformational plasticity and ligand-dependent signaling" provides a groundbreaking look at the Growth Hormone-Releasing Hormone Receptor (GHRHR), a Class B1 G protein-coupled receptor (GPCR) vital for growth and metabolism. While traditional models have struggled to capture the dynamic nature of such receptors, this study utilizes high-resolution cryogenic electron microscopy (cryo-EM) and molecular dynamics (MD) simulations to map the receptor's structural landscape across multiple functional states.
The core objective of the research is to understand how GHRHR adapts its structure to prefer specific signaling pathways when stimulated by different ligands. The study successfully resolved the structures of the receptor in its ligand-free (Apo) active state, its state bound to a small-molecule allosteric agonist (PCO371), and its inactive state bound to a peptidic antagonist (MIA-602).
A key innovation is the discovery of how PCO371, an allosteric agonist, binds to a unique intracellular site. Unlike traditional agonists that trigger reorganization from the extracellular side, PCO371 stabilizes the active interface from within, providing a structural basis for "biased signaling"—the ability of a receptor to activate one intracellular pathway over another. Conversely, the antagonist MIA-602 was found to lock the receptor in an inactive conformation by pinning a conserved "HETY" motif, effectively preventing the structural movements required for G protein engagement.
The implications for drug discovery are significant. By providing an atomic-level template of these "on" and "off" states, the study paves the way for the design of precision therapeutics. These could include highly selective agonists to treat growth hormone deficiency and dwarfism, or potent antagonists to combat hormone-dependent tumors and acromegaly. Ultimately, this research transforms our understanding of GPCR signaling from static snapshots into a dynamic, actionable framework for drug development.
DOI：10.1093/procel/pwag016